Single-Cell Dissection of the Immune Response After Acute Myocardial Infarction
Irene V. van Blokland,Roy Oelen,Hilde E. Groot,Jan Walter Benjamins,Kami Pekayvaz,Corinna Losert,Viktoria Knottenberg,Matthias Heinig,Leo Nicolai,Konstantin Stark,Pim van der Harst,Lude Franke,Monique G.P. van der Wijst
DOI: https://doi.org/10.1161/circgen.123.004374
2024-05-18
Circulation Genomic and Precision Medicine
Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. BACKGROUND:The immune system's role in ST-segment–elevated myocardial infarction (STEMI) remains poorly characterized but is an important driver of recurrent cardiovascular events. While anti-inflammatory drugs show promise in reducing recurrence risk, their broad immune system impairment may induce severe side effects. To overcome these challenges, a nuanced understanding of the immune response to STEMI is needed.METHODS:For this, we compared peripheral blood mononuclear single-cell RNA-sequencing (scRNA-seq) and plasma protein expression over time (hospital admission, 24 hours, and 6–8 weeks post-STEMI) in 38 patients and 38 controls (95 995 diseased and 33 878 control peripheral blood mononuclear cells).RESULTS:Compared with controls, classical monocytes were increased and CD56dimnatural killer cells were decreased in patients with STEMI at admission and persisted until 24 hours post-STEMI. The largest gene expression changes were observed in monocytes, associating with changes in toll-like receptor, interferon, and interleukin signaling activity. Finally, a targeted cardiovascular biomarker panel revealed expression changes in 33/92 plasma proteins post-STEMI. Interestingly, interleukin-6R, MMP9 (matrix metalloproteinase-9), and LDLR (low-density lipoprotein receptor) were affected by coronary artery disease–associated genetic risk variation, disease status, and time post-STEMI, indicating the importance of considering these aspects when defining potential future therapies.CONCLUSIONS:Our analyses revealed the immunologic pathways disturbed by STEMI, specifying affected cell types and disease stages. Additionally, we provide insights into patients expected to benefit most from anti-inflammatory treatments by identifying the genetic variants and disease stage at which these variants affect the outcome of these (drug-targeted) pathways. These findings advance our knowledge of the immune response post-STEMI and provide guidance for future therapeutic studies.
genetics & heredity,cardiac & cardiovascular systems